Citius Oncology, Inc. CTOR Other Research And Development Expense
Other Research And Development Expense at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s other research and development expense?
- Citius Oncology, Inc. (CTOR) reported other research and development expense of $469K in Q1 2026.
- How has Citius Oncology, Inc.'s other research and development expense changed year-over-year?
- Citius Oncology, Inc.'s other research and development expense decreased by 2.3% year-over-year, from $480K to $469K.
- What is the long-term trend for Citius Oncology, Inc.'s other research and development expense?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s other research and development expense has grown at a 13.3% compound annual growth rate (CAGR), from $1.5M to $1.92M.
- What does other research and development expense mean?
- Represents miscellaneous research and development costs that do not fall under primary project categories. This metric captures ancillary R&D spending necessary for supporting clinical or preclinical operations.